Early indications suggest that 2017 can avoid a repeat of 2016's disappointing decline in novel approvals from FDA. The agency is reviewing more than 40 new molecular entities and novel biologics, and the window for submissions to receive a 2017 user fee goal date is open for another two months.
FDA has already approved eight products with 2017 user fee goal dates. Four were cleared in 2016 ahead of the...






